Coronavirus (COVID-19)
Learn more
April 11, 2017
Sponsor: National Cancer Institute (NCI)
Number: NRG GI-002
Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) trial studies how well Veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started, to nearby tissue or lymph nodes (locally advanced). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs used, such as modified (m) FOLFOX6 regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving Veliparib with combination chemotherapy and radiation therapy may kill more tumor cells. Giving it before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Who’s eligible:
Available at: The Hospital of Central Connecticut, MidState Medical Center, Backus Hospital- Eastern Connecticut Hematology and Oncology, and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209